Drug Profile
Research programme: JAK2 inhibitor - Bristol-Myers Squibb
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Small molecules
- Mechanism of Action Janus kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Haematological-malignancies in USA
- 03 Mar 2010 Preclinical trials in Haematological malignancies in USA (unspecified route)